[Abstract Only] Randomized Trial: Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Targeted therapy drug helps women with aggressive breast cancer live longer – University of California (free) AND Overall Survival With the Addition of Ribociclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: MONALEESA-3 – The ASCO Post (free)